<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738777</url>
  </required_header>
  <id_info>
    <org_study_id>N08AFT</org_study_id>
    <secondary_id>EudraCT; 2008-000644-13</secondary_id>
    <nct_id>NCT00738777</nct_id>
  </id_info>
  <brief_title>Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer</brief_title>
  <official_title>A Randomized, Prospective Trial of 2-6 Weeks Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer: Anastrozole +/- Fulvestrant or Tamoxifen Exposure - Response in Molecular Profile (AFTER-study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate prospectively whether short term endocrine treatment can induce molecular&#xD;
      changes, predictive for therapy response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will perform a randomized, open-label, single-institution study. It will compare the&#xD;
      efficacy of three different endocrine treatment regimens (Anastrozole +/- Fulvestrant or&#xD;
      Tamoxifen) in changing proliferation-index and inducing apoptosis during a 2-6 week&#xD;
      pre-operative treatment period in breast cancer patients. These results will be correlated to&#xD;
      gene expression profiles, phosphorylation status of the ER, SNPs in CYP450 sequences,&#xD;
      tamoxifen metabolite concentrations, changes in estrogen serum levels and protein expression&#xD;
      patterns.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    in preparation for an amendment&#xD;
  </why_stopped>
  <start_date type="Actual">July 2008</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in tumor cell proliferation and induced apoptosis.</measure>
    <time_frame>At baseline and after 2-6 weeks of endocrine treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of changes in gene expression after different endocrine treatment exposures</measure>
    <time_frame>At baseline and after endocrine treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anastrozole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anastrozole + Fulvestrant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamoxifen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tamoxifen (pre-menopausal and male patients)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>1 mg,QD,PO</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole+Fulvestrant</intervention_name>
    <description>Anastrozole; 1 mg, QD, PO Fulvestrant; 500 mg, IM, day 1, 15, 29 and monthly thereafter</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with proven invasive adenocarcinoma of the breast&#xD;
&#xD;
          -  Any tumor with a size â‰¥ 1cm (NOT inflammatory breast cancer)&#xD;
&#xD;
          -  WHO-performance score 0 or 1&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clues of metastatic disease by clinical examination according to most recent NABON&#xD;
             guidelines&#xD;
&#xD;
          -  Multicentric breast cancer&#xD;
&#xD;
          -  Inflammatory breast cancer&#xD;
&#xD;
          -  Hormone replacement during the last 12 months&#xD;
&#xD;
          -  Other systemic treatment during the waiting time till surgery&#xD;
&#xD;
          -  Already planned date for surgery within the next 2 weeks&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering adequate informed consent or compliance with the study protocol&#xD;
&#xD;
          -  Patient's refusal to undergo a core biopsy procedure of the primary tumor before the&#xD;
             start of treatment&#xD;
&#xD;
        NB: a concomitant malignancy within the last five years is not an exclusion criterium,&#xD;
        because survival is not the primary endpoint. Just as prior invasive breast cancer or DCIS&#xD;
        within the last 15 years is not an exclusion criterium.&#xD;
&#xD;
        NB: Patients of childbearing potential must implement adequate non-hormonal contraceptive&#xD;
        measures during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine C Linn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden</name>
      <address>
        <city>den Haag</city>
        <state>ZH</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NKI-AVL</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 19, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pre-operative</keyword>
  <keyword>endocrine treatment</keyword>
  <keyword>drug resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

